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A 32 year old nulliparous woman with morbid obesity (body mass
index 39.7) presented with heavy vaginal bleeding. Endometrial
sampling demonstrated endometrioid endometrial adenocarcinoma,
FIGO grade 1. Magnetic resonance imaging showed no evidence of
myometrial invasion or extrauterine disease. Her family history was
signiﬁcant for two aunts with breast cancer. The patient was recom-
mended surgical treatment with hysterectomy, bilateral salpingo-
oophorectomy and lymph node dissection as standard of care, butIntroduction
Endometrial carcinoma is the most common gynecologic malignan-
cy in the United States. With the growing obesity epidemic, an increas-
ing number of women are diagnosed prior to menopause when fertility
is desired (Gallup and Stock, 1984; Kim et al., 2013). While hysterecto-
my and bilateral salpingo-oophorectomy are standard of care, multiple
studies have described the feasibility and safety of treating atypical
endometrial hyperplasia and low grade carcinoma with high dose pro-
gestin therapy (Wang et al., 2014; Simpson et al., 2014). Progesterone
therapy for endometrial neoplasia has been reported to commonly
cause hyperglycemia, hypertension, nausea, vomiting, weight gain,
and sexual dysfunction, but can also cause more serious reactions
including pulmonary embolus, diabetes, adrenal suppression and
cardiomyopathy (Thigpen et al., 1999). Progesterone is also known to
increase the risk of breast cancer in women undergoing hormonal
replacement therapy (Manson et al., 2013; Beral and Million Women
Study Collaborators, 2003), however, breast cancer in a woman under-
going hormonal treatment for endometrial cancer has not been de-
scribed. Here we report a case of advanced breast cancer in a 32 year
old woman who had undergone hormonal therapy for fertility sparing
treatment of endometrial cancer.ology, 240 East 38th Street, 19th
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. This is an open access article underdesired fertility preservation and elected a trial of conservativemanage-
ment. She was enrolled on a clinical trial that prescribed megestrol
acetate, 160 mg daily. She was offered genetic and nutritional counsel-
ing but declined.
The patient underwent regular endometrial sampling and demon-
strated a complete response bydilatation and curettage after 14 months
of treatment. She desired immediate fertility andwas referred to repro-
ductive endocrinology to expedite pregnancy, with sampling recom-
mended at six months interval if fertility was not achieved. She
represented one year later not having become pregnant and a surveil-
lance biopsy demonstrated recurrent FIGO grade 1 endometrial cancer.
At this visit she also reported irregular vaginal spotting. The patientwas
again recommended standard of care surgical management and weight
loss strategies but declined and resumed megestrol acetate. Nine
months later she had complete resolution of disease on a dilation and
curettage specimen. She returned for fertility treatment, but did not be-
come pregnant and a surveillance biopsy 8 months later demonstrated
complex hyperplasia without atypia. The patient elected to restart
megestrol acetate, however after just 4 weeks reported bothersome ab-
dominal pain and nausea. The systemic progesterone was discontinued
and a progesterone-releasing intrauterine device (IUD)was placed. The
patient was seen four weeks later and reported right breast pain. On
physical exam and imaging she was found to have a 5 cm irregular
mass with enlarged right axillary lymph nodes. A breast biopsy demon-
strated poorly differentiated invasive ductal carcinoma that was estro-
gen and progesterone receptor positive. An axillary lymph node ﬁne
needle aspiration revealed malignant cell consistent with stage cT3N1
breast cancer.
An interdisciplinary meeting was called with the patient's medical,
surgical and gynecologic oncology teams. The consensus plan was to
treat the breast cancer while keeping the IUD in place and then proceed
with hysterectomy, bilateral salpingo-oophorectomy and lymph node
dissection. She received neoadjuvant adriamycin, cyclophosphamide,the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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chemotherapy with new dermal involvement. She underwent a
bilateral mastectomy and axillary lymph node dissection and on ﬁnal
pathology had involvement of multiple axillary lymph nodes She re-
ceived postoperative radiation therapy. The patient's menses ceased
with chemotherapy, she has not had additional bleeding and the most
recent endometrial sampling demonstrated complete resolution of dis-
ease. The patient plans to undergo Letrozole-triggered oocyte retrieval
and will then undergo deﬁnitive surgical management for her endome-
trial cancer.
Discussion
While the average age of diagnosis of endometrial cancer is 61,
25% of cases occur in pre-menopausal women and 3–5% of new cases
occur in women 40 years or younger (Gallup and Stock, 1984). The
standard treatment for endometrial carcinoma is total extra-fascial
hysterectomy, bilateral salpingo-oophorectomy, and lymph node as-
sessment. However, premenopausal women with endometrial carcino-
ma often desire maintenance of fertility and multiple studies support
progesterone therapy as a safe and effective treatment for endometrial
hyperplasia and low grade carcinoma (Wang et al., 2014; Simpson
et al., 2014). In 2004, Ramirez et al. (2004) reported a response rate of
76% among patients with well differentiated endometrial carcinoma
who were treated with progesterone. Additionally, a recent systematic
review of forty-ﬁve studies demonstrated a 78% complete response
rate (Gunderson et al., 2012).
Progesterone is a steroid hormone that is essential for coordinating
normal female reproductive physiology. The effect of progesterone is
known to differ by tissue type and location. While in the endometrium
progesterone has a protective effect against estrogen-dependent carci-
nogenesis, in breast tissue it has a pro-proliferative role, expanding a
stem cell population that is sensitive to transformation (Kim et al.,
2013). Basic science research supports the role of progestins in breast
tumorigenesis. Tissue samples from breast cancer specimens demon-
strate an increased percentage of proliferating estrogen and progester-
one receptor-positive cells (Kim et al., 2013). An overexpression of
progesterone receptors has been observed in mice deﬁcient in BRCA1
and p53,mutations known to be associatedwith increased risk of breast
cancer. Furthermore, treatment of mutant mice with the progesterone
antagonist mifepristone can prevent mammary tumorigenesis (Kim
et al., 2013). Neubauer et al. (2011) incubated breast cancer cells with
increasing estradiol concentrations and different progestins and found
that medroxyprogesterone resulted in an increased proliferation of
breast cancer cells.
This case is notable because treatment for one cancer may have re-
sulted in a second cancer. While the association between progesterone
and breast cancer is well recognized in the population of womenreceiving hormone replacement therapy, it has not been clearly
established among young women undergoing medical treatment for
endometrial cancer.Whenwomen elect to undergo treatmentwith pro-
gestins for conservative management of endometrial neoplasia, the
counseling usually focuses on the risk of persistence or progression of
the endometrial cancer. Of note, this patient had other risk factors for
the development of breast cancer including family history of breast can-
cer, a possible undiagnosed familial cancer syndrome and obesity.
Whether progestins, genetics, obesity or a combination of factors con-
tributed to this cancer diagnosis remains unclear. Nevertheless, this
case highlights the importance of thorough counseling prior to pursuing
conservative management of endometrial cancer and further studies
exploring the side effects of high dose progesterone in young women
with endometrial cancer.
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